Ptc Therapeutics (PTCT) Debt to Equity (2016 - 2025)
Historic Debt to Equity for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to -$1.84.
- Ptc Therapeutics' Debt to Equity fell 25711.82% to -$1.84 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 25711.82%. This contributed to the annual value of -$0.49 for FY2024, which is 1537.53% up from last year.
- Ptc Therapeutics' Debt to Equity amounted to -$1.84 in Q3 2025, which was down 25711.82% from -$2.65 recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' Debt to Equity ranged from a high of $300.02 in Q4 2021 and a low of -$4.77 during Q1 2022
- Moreover, its 5-year median value for Debt to Equity was -$1.01 (2023), whereas its average is $14.94.
- Its Debt to Equity has fluctuated over the past 5 years, first skyrocketed by 4369770.18% in 2021, then plummeted by 40223.19% in 2025.
- Quarter analysis of 5 years shows Ptc Therapeutics' Debt to Equity stood at $300.02 in 2021, then crashed by 100.62% to -$1.86 in 2022, then skyrocketed by 68.49% to -$0.58 in 2023, then rose by 15.38% to -$0.49 in 2024, then tumbled by 271.57% to -$1.84 in 2025.
- Its Debt to Equity was -$1.84 in Q3 2025, compared to -$2.65 in Q2 2025 and -$2.87 in Q1 2025.